Eyecare giant Bausch + Lomb is to distribute ophthalmic surgical microscopes built by Leica Microsystems, after the two firms agreed a deal covering "select" global markets. The deal expands Bausch + ...
Bausch + Lomb Stock Under the Microscope: A Quiet Grind Higher With Cautious Optimism on Wall Street
Bausch + Lomb’s stock has been edging higher on light newsflow, leaving investors to weigh steady execution against modest growth expectations, regulatory overhangs, and a still?patient Wall Street.
Bausch + Lomb is positioned as a turnaround and deleveraging opportunity, benefiting from a shift toward higher-margin products and expanding global distribution. Q2 2026 results showed broad-based ...
StockStory.org on MSN
Bausch + Lomb (NYSE: BLCO) posts Q3 2026 profit well ahead of estimates
Eyecare company Bausch + Lomb (NYSE:BLCO) exceeded in Q3 2026, with revenue up 7.3% year on year to $1.38 billion. The ...
Most of the moving images which U. S. cinemaudiences goggle at are projected through Bausch & Lomb lenses. Bausch & Lomb’s 17,000 other products include spectacles, microscopes (15,000 a year), gun ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results